Cargando…

Checkpoint inhibitor-related renal vasculitis and use of rituximab

The percentage of patients with cancer eligible for checkpoint inhibitor (CPI) therapy has increased rapidly over the past few years and approaches 45%. As a result, more cases of CPI-related nephrotoxicity, including a rare subset with vasculitis, are being reported. To elucidate the clinical prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mamlouk, Omar, Lin, Jamie S, Abdelrahim, Maen, Tchakarov, Amanda S, Glass, William F, Selamet, Umut, Buni, Maryam, Abdel-Wahab, Noha, Abudayyeh, Ala
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380836/ https://www.ncbi.nlm.nih.gov/pubmed/32718987 http://dx.doi.org/10.1136/jitc-2020-000750

Ejemplares similares

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
por: Lin, Jamie S., et al.
Publicado: (2021)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury
por: Abudayyeh, Ala, et al.
Publicado: (2022)

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
por: Parvathareddy, Vishnupriyadevi, et al.
Publicado: (2023)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

RNAi and cancer: Implications and applications
por: Abdelrahim, Maen, et al.
Publicado: (2006)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
por: Strasma, Anna, et al.
Publicado: (2021)

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma
por: Hedrick, Erik, et al.
Publicado: (2015)

Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma
por: Ratanasrimetha, Praveen, et al.
Publicado: (2022)

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?
por: Abudayyeh, Ala, et al.
Publicado: (2015)

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022)

Rituximab-Associated Flare of Cryoglobulinemic Vasculitis
por: Sy-Go, Janina Paula T., et al.
Publicado: (2021)

Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment
por: Arman, Farid, et al.
Publicado: (2018)

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis
por: Fornero, Léa, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab for the Treatment of Pediatric Double-Positive Small-Vessel Vasculitis
por: Timmermans, Sjoerd A.M.E.G., et al.
Publicado: (2019)

Successful treatment of idiopathic retinal vasculitis with rituximab in two patients
por: Apivatthakakul, Atitaya, et al.
Publicado: (2023)

Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates
por: Singh, Shailbala, et al.
Publicado: (2022)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab
por: Fenoglio, Roberta, et al.
Publicado: (2022)

Noninfectious, Severe Cryoglobulinemic Vasculitis with Renal Involvement – Safety and Efficacy of Long-Term Treatment with Rituximab
por: Leśniak, Ksymena, et al.
Publicado: (2021)

Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Burns, Ethan A., et al.
Publicado: (2021)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
por: Abdel-Wahab, Noha, et al.
Publicado: (2016)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2jt8h8hg7c8gkpflllt4qqdgsr